Table 3.
Intervention | Indication | Clinical stage | Sponsor |
---|---|---|---|
PEG-rIL-29 | Hepatitis C | Phase I NCT00565539 Phase II NCT01001754 |
ZymoGenetics |
PEG-rIL-29 | Hepatitis C | Phase III NCT01718158 Phase III NCT01598090 Phase III NCT01754974 Phase III NCT01866930 Phase III NCT01616524 |
Bristol-Myers Squibb |
PEG-rIL-29 | Hepatitis D | Phase II NCT02765802 | Eiger BioPharmaceuticals |
Data source: clinicaltrials.gov.